ArticleDiabetes & metabolism2020
SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
Article in Diabetes & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.Diabetes research and clinical practice · 2023Pooled it
- Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial.The lancet. Diabetes & endocrinology · 2024Trial
- SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-Analysis, and Bayesian Sensitivity Assessment.Diseases (Basel, Switzerland) · 2025Review
- Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?Journal of cardiovascular development and disease · 2023Review
- Clinical characteristics and acute complication of COVID-19 patients with diabetes: a multicenter, retrospective study in Southern China.Frontiers in endocrinology · 2023Article
- Novel Strategies for the Treatment of COVID-19.Drugs in R&D · 2022Article
- The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?Cardiovascular diabetology · 2021Article
- Early and late endocrine complications of COVID-19.Endocrine connections · 2021Review
- Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.Diabetes care · 2021Article
- Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.Diabetes, obesity & metabolism · 2021Article
- DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.Diabetes & metabolism · 2021Review
- Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus.Journal of clinical medicine · 2020Review
- Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Metformin and COVID-19: From cellular mechanisms to reduced mortality.Diabetes & metabolism · 2020Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.